Celgene (CELG): Reiterating Buy On Improved Outlook For Chron's Therapy - BMO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Leerink Affirms Celgene (CELG) at 'Market Perform'; Doesn't see Strong Mongersen Phase 2 Data Translating to Phase 3
September 12, 2016 11:31 AM EDTLeerink affirms Celgene Corporation (Nasdaq: CELG) at Market Perform with a price target of $135 after the company announced interim topline data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects of oral GED-0301 (mongersen) on both endoscopic and clinical outcomes in patients with active Crohns disease.
The firm commented,... More
Baird 'Incrementally Negative' After Celgene (CELG) GED-0301 Data a Non-Event
September 12, 2016 11:02 AM EDTBaird analyst Brian Skorney said he is incrementally negative after Celgene (NASDAQ: CELG) on GED_0301 results. The firm, however, maintained a Outperform rating and price target of $162.00.
Skorney commented, "Celgene's big 2H16 catalyst turned out to be a non-event, as the topline... More
